Boston Scientific (BSX) to Release Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Boston Scientific to post earnings of $0.78 per share and revenue of $5.2896 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:00 AM ET.

Boston Scientific Stock Up 0.1%

Boston Scientific stock opened at $93.63 on Wednesday. The company has a fifty day simple moving average of $95.42 and a 200 day simple moving average of $99.69. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a market cap of $138.81 billion, a P/E ratio of 50.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.67.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Evercore ISI set a $112.00 target price on Boston Scientific in a report on Monday, January 5th. Royal Bank Of Canada increased their price objective on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Finally, Leerink Partners lifted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $123.89.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 80,204 shares of company stock valued at $7,998,563 over the last ninety days. 0.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Pin Oak Investment Advisors Inc. acquired a new stake in Boston Scientific in the 3rd quarter worth about $41,000. Johnson Financial Group Inc. boosted its holdings in Boston Scientific by 196.4% in the 3rd quarter. Johnson Financial Group Inc. now owns 735 shares of the medical equipment provider’s stock valued at $72,000 after purchasing an additional 487 shares during the period. Seldon Capital LP acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $208,000. Finally, Victory Financial Group LLC increased its holdings in shares of Boston Scientific by 14.3% during the third quarter. Victory Financial Group LLC now owns 2,216 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 278 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.